The Partnership to Amend 42 CFR Part 2, a coalition of nearly 50 health care organizations committed to aligning 42 CFR Part 2 with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO), today issued the following statement in response to the bipartisan passage of the Coronavirus Aid, Relief, and Economic Security Act.
Aligning stakeholder perspectives, providing timely and meaningful drug pricing information, and establishing common definitions of health care value could help ensure patients are able to access medications they need at costs they can afford.
AMCP has released Version 4.1 of the AMCP Format for Formulary Submissions, which includes two new dossier types for biopharmaceutical manufacturers to share evidence on unapproved products and new indications that are under review by the U.S. Food and Drug Administration (FDA).
Increased simplicity, broader financial risk sharing, and an enhanced focus on patient care were among the recommendations developed by diverse stakeholders at a recent AMCP Partnership Forum focused on how to better manage the high costs of specialty medications.
National Harbor, Md., Oct. 29, 2019 — AMCP Nexus 2019 will welcome nearly 2,500 managed care pharmacy professionals from across the country this week for four days of educational and networking programs focused on the “intersection of value and care.”
AMCP announced today that Phil Bongiorno has joined the organization as vice president, policy & government relations. In this role, he will oversee AMCP’s many advocacy efforts to advance managed care pharmacy principles and practices through health care legislation and regulation at both the federal and state levels.
AMCP last week gathered a group of diverse health care stakeholders to discuss the challenges and opportunities of ensuring patient access to a category of emerging therapies known as “digital therapeutics,” which have the potential to treat a wide range of diseases and medical conditions.
Press Release: The Trump Administration today pulled its proposed rule to eliminate safe harbor protections for rebates paid by pharmaceutical manufacturers to PBMs and health plans in Medicare and Medicaid programs.
Press Release: Focusing on what’s best for the patient, leveraging technology to perform real-time benefit checks, and developing trust and transparency among stakeholders are some of the suggestions to emerge from AMCP’s recent Partnership Forum on “Optimizing Prior Authorization for Appropriate Medication Selection.”
Press Release: The Academy of Managed Care Pharmacy (AMCP) has developed nine concepts around the effective use of prior authorization that managed care organizations can follow to ensure that PA processes are timely, transparent, collaborative and supportive of patient-centered care.
Press Release: From News&Views April 2019: The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies.
Press Release: According to a newly released survey from AMCP, nearly 63 percent of Medicare beneficiaries say they would recommend MTM services provided under the Part D prescription drug program to friends and relatives.
Press Release: AMCP CEO Susan A. Cantrell, RPh, CAE, issued the following statement on HHS’s proposed rule to eliminate negotiated rebates for pharmaceuticals under Medicare Part D and managed Medicaid programs.
Press Release: The prevalence of those diagnosed with opioid-related disorders in the Medicare fee-for-service (FFS) population is higher than among any other studied payer groups, and the majority of disorders were found among those receiving Medicare based on disability.